The initial success of Sildenafil undeniably reshaped the medication landscape, but betting in companies heavily reliant on unbranded versions presents a challenging picture. Although early profits were significant, the end of patents and the appearance of less expensive alternatives have eroded sales. Therefore, a thorough assessment of present fi